33 results about "Cytosine nucleotide" patented technology

Provided are methods and systems for detecting formation of nucleotide-specific ternary complexes comprising a DNA polymerase, a nucleic acid, and a nucleotide complementary to the templated base of the primed template nucleic acid. The methods and systems facilitate determination of the next correct nucleotide without requiring chemical incorporation of the nucleotide into the primer. These results can even be achieved in procedures employing unlabeled, native nucleotides.

A method for identifying target alleles, that includes steps of (a) forming a plurality of stabilized ternary complexes at a plurality of features on an array, wherein the stabilized ternary complexes each has a polymerase, a template nucleic acid having a target allele of a locus, a primer hybridized to the locus, and a next correct nucleotide having a cognate in the locus, wherein either (i) the primer is an allele-specific primer having a 3′ nucleotide that is a cognate nucleotide for the target allele, or (ii) the primer is a locus-specific primer and the next correct nucleotide hybridizes to the target allele; and (b) detecting stabilized ternary complexes at the features, thereby identifying the target alleles.

The invention discloses a feed for preventing and controlling tortoise-turtle red white disease, and belongs to the technical field of tortoise-turtle feed processing. The feed comprises the following raw materials: ampullaria gigas, potatoes, cassava, earthworms, acridid, salt, dimethyl-beta-dimethylpropiothetin, glycine betaine, phenylalanine, cytidylate, sodium diacetate, stevioside, and Chinese herbal and crude drugs preparations. The feed is prepared by drying, crushing, screening, mixing, pelletizing, drying, cooling and packaging. The feed synthesizes the effects of Chinese herbal and crude drugs, and can play the effects of clearing away heat and toxic materials, cooling blood and swelling, and resisting bacteria and resisting inflammation, the tortoise-turtle disease resistance is enhanced so as to effectively prevent and control tortoise-turtle red white disease and reduce the death rate of the tortoise-turtle; the feed is abundant in nutrition, reasonable in preparation, and capable of improving the tortoise-turtle palatability, increasing tortoise-turtle food consumption and growth speed, and shortening the production period; the feed disclosed by the invention adopts a simple preparation method, strong in operability and easy to popularize.

The invention discloses a quality control method for ribonucleic acid II for injection. The method comprises the following steps that the nucleic acid enzyme hydrolysis solution of a substance to be measured is subjected to high-performance liquid chromatogram analysis, an adopted chromatographic column is an Agilent ZORBAX SB-AQC18 chromatographic column, and a flowing phase is a mixture of a formic acid solution and an acetonitrile solution; after the analysis, if the substance to be measured is determined to contain five substances as follows: cytidylate, uridine monophosphate, guanine nucleotide, guanosine and adenosine, the substance to be measured is the ribonucleic acid II for injection or is the ribonucleic acid II for injection as a candidate; and if not, the substance to be measured is not the ribonucleic acid II for injection or is not the ribonucleic acid II for injection as the candidate. A high-performance liquid chromatographic technique is utilized, and the strong-specificity quality control method for the ribonucleic acid II for injection is established. The method has important meanings on increasing the technological content of the medicine, increasing the safety and effectiveness, reducing the cost, enlarging the production scale, increasing the market occupancy, and going forward to the international market.

The invention discloses a chemical labeling and LC-MS combined method, and applications thereof in nucleotide analysis. According to the chemical labeling and LC-MS combined method, N,N-dimethyl-p-phenylenediamine is used for chemical labeling of 10 monophosphate nucleotides containing two methylation modified nucleotides, so that the retention behavior of the modified nucleotides in reversed phase liquid chromatography is improved obviously, and detection sensitivity of the modified nucleotides in mass spectrometric detection is increased. The chemical labeling and LC-MS combined method is high in sensitivity and selectivity; liquid-liquid extraction can be adopted to remove excess labeling reagent DMPA effectively, Strata X solid phase extraction columns can be used for removing excess activator EDC, quantitative determination of extremely-low-abundance methylation modified cytidylate in living bodies can be realized, LC separation sensitivity and ESI-MS detection sensitivity of nucleotides can be improved obviously, and signal responsiveness is increased by 1 to 2 magnitude orders.

The invention discloses a herpes zoster vaccine composition as well as a preparation method and application thereof, and belongs to the field of vaccines. The vaccine composition comprises varicella-zoster glycoprotein E, a polylactic acid-polyglycolic acid copolymer (PLGA), a double-stranded polycytosine nucleotide fragment (Poly I: C) and a GC-rich single-stranded oligodeoxynucleotide fragment (CpG ODN), the particles with the diameter of 20-400 nanometers are prepared through microfluidic equipment or a double-emulsifying-medium evaporation method. The vaccine composition can specifically enhance humoral immune response and cellular immune response to varicella-zoster glycoprotein E, and can be used as a herpes zoster vaccine; and the components in the vaccine composition are cheap andeasily available, so that the vaccine cost is effectively reduced, and the vaccine yield is increased.

The present invention provides a method of evaluating DNA methylation in a sample. The method comprises (i) reacting the DNA with an agent that differentially modifies methylated cytosine and non-methylated cytosine to produce modified DNA, (ii) amplifying the modified DNA by methylation specific PCR to produce amplified DNA, and (iii) subjecting the amplified DNA to melting analysis. In the method the methylation specific primers are selected such that the sequence between the primers includes a region of known sequence variation and / or at least one cytosine nucleotide.

The invention discloses a kit for detecting congenital aniridia pathogenic gene mutation and application of the kit. Detected pathogenic gene mutation is mutation of 140th-position adenine nucleotideof a second exon of a PAX6 gene into cytidylate, namely, NM_000280.3: c.140 A>C. The kit for detecting the congenital aniridia pathogenic gene mutation comprises a 10 * PCR buffer solution, 25 mM dNTPs, DNA polymerase, a PCR amplification primer pair and ddH2O, wherein the PCR amplification primer pair consists of a primer 1 (as shown in SEQ ID NO: 1) and a primer 2 (as shown in SEQ ID NO: 2). Thekit provides a novel congenital aniridia detection means, can provide genetic diagnosis and genetic counseling for clinically conformed congenital aniridia patients, and can provide genetic diagnosisfor eye abnormal patients with undetermined phenotypes to guide clinic treatment.

The invention discloses a feed for treating a fatty liver disease of turtles and a preparation method thereof, and belongs to the technical field of turtle feed processing. The feed is prepared from, by weight, 30-50 parts of silkworm pupa meal, 50-70 parts of manihot utilissima powder, 8-16 parts of table salt, 6-14 parts of dimethyl-beta-propiothetin, 5-9 parts of betaine, 4-8 parts of glycine, 4-8 parts of cytidylic acid, 0.2-0.6 part of Tomatin polypeptide, 1-3 parts of citronellal and 15-42 parts of traditional Chinese medicine preparation. The feed is prepared through the steps of drying, smashing, screening, liquid medicine extracting, concentrating, mixing, pelletizing, sterilizing and the like. According to the feed for treating the fatty liver disease of the turtles, the effects of multiple traditional Chinese medicines are synthesized, the effects of resisting bacteria, diminishing inflammation, enhancing the body immune function and the like can be achieved, the cure rate of the fatty liver disease of the turtles can be effectively increased, and the death rate of the fatty liver disease of the turtles can be effectively decreased; the feed is reasonable in preparation, rich in nutrition and capable of increasing the feed intake of the turtles suffering from the fatty liver disease and increasing the growth speed.

The invention relates to a compound nucleotide immunoenhancer for paralichthys olivaceus, which is composed of the following substances in percentage by weight: 55-65% of cytidylate, 5-15% of uridine monophosphate, 5-15% of thymidine phosphorylase, 1-5% of hypoxanthine nucleotide and 10-20% of bioactive peptide. The compound nucleotide immunoenhancer disclosed by the invention is capable of obviously improving the ingestion and the growth of paralichthys olivaceus, and remarkably improving the cellular immunity, the humoral immunity, the immune gene expression quantity, the disease resistance and the like of paralichthys olivaceus. Moreover, the compound nucleotide immunoenhancer can also be directly added in a feed for paralichthys olivaceus, and orally fed; and the compound nucleotide immunoenhancer has the advantages of being free from toxic and side residues, free from drug resistance, and pollution-free to environment.

The invention belongs to the field of vaccines, and particularly provides a varicella-herpes zoster vaccine composition as well as a preparation method and an application thereof. The vaccine composition contains varicella-herpes zoster glycoprotein E, lipid nanoparticles (LNP), a double-stranded polycytosine nucleotide fragment (Poly I: C) and a GC-rich single-stranded oligodeoxynucleotide fragment (CpG ODN), or contains gE, LNP and CpG ODN. Particles with the diameter of 20-400nm are prepared through a microfluidic device. The vaccine composition can specifically enhance humoral immune response and cellular immune response targeting the varicella-herpes zoster glycoprotein E, and can be used as a varicella vaccine without causing latent infection of vaccine strains, or as a herpes zoster vaccine. The vaccine composition has cheap and available components, thereby reducing the vaccine cost and improving vaccine yield.

The invention discloses a new oral liquid of compound nucleotide and preparation thereof. Each ml. of said compound nucleotide oral liquid comprising the following nucleotide in weight: adenylic acid 0.68-0.76mg, guanylic acid 0.43-0.52mg, uridylate 0.5-0.67mg, cytidylic acid 0.42-0.55mg and thymidylic acid 0.22-0.25mg.

The present invention relates to a method for detecting methylation of a target oligonucleotide molecule. The method comprises obtaining an electrical change occurring due to the binding of an electrically charged methylation detecting molecule and the target oligonucleotide molecule; wherein the electrically charged methylation detecting molecule has affinity to a methylated cytosine nucleotide. The invention improves the detection sensitivity and accuracy of the oligonucleotide methylation detection.

The invention belongs to the field of biotechnology, and in particular relates to an engineering bacterium containing nCas3 single-stranded endonuclease, a preparation method and an application. This application finds the functional structure division of its Cas3 protein by comparing the differences in the coding gene sequences of endogenous CRISPR-related proteins between the ZM4 strain and other strains that also carry the endogenous type I CRISPR-Cas system. And by exploring the working principle of the I‑F CRISPR‑Cas system, an amino acid in the helicase domain of the Cas3 protein in the ZM4 strain was designed and replaced. The adenine nucleotide number 676,661 in the ZMO0681 gene encoding the Cas3 protein on the original ZM4 strain was replaced with a cytosine nucleotide in situ, so that the Cas3 protein lost the helicase activity and transformed into a single-stranded DNA endonuclease The enzymatically active nCas3 protein was obtained to obtain the modified strain DRM2.

The invention relates to the technical field of preparation of polypropylene anticorrosive materials, and discloses a polypropylene anti-corrosion material based on a biomass cytosine flame retardant.The polypropylene anti-corrosion material comprises the following raw materials in parts by weight: a cytosine flame retardant, polypropylene, an antioxidant and a flexibilizer, wherein the flexibilizer is a mixture of an ethylene-vinyl acetate copolymer, thermoplastic elastomer and powdered rubber. According to the polypropylene anti-corrosion material based on the biomass cytosine flame retardant, a cytosine derivative, cytidylic acid and tris(epoxypropyl)isocyanurate are subjected to a condensation reaction to generate tri(epoxypropyl)isocyanocytidylic acid, and aluminum hydroxide is addedto react with phosphate groups to generate a salt, so that the biomass cytosine aluminum salt with a flame-retardant effect is achieved. The flame retardant improves integrity of the polypropylene material forming a form of expanded carbon, then carbon on the surface layer of carbon layer is compact, and the inner layer is porous, so that flame-retardant efficiency of the polypropylene material is effectively improved, the adding amount is small, and the flame-retardant effect is good.

A nucleic acid vaccine for preventing and treating atherosolerosis and its preparing process are disclosed. The core protein of hepatitis B is used as its immune carrier to intensify the immunogenicity of CETPC. The body immunized by said vaccine can generate CETPC antibody to suppress the activity of cholesteryl ester transfer protein, so decreasing the generation of atherosclerosis spots. It can also act on the formed atherosclerosis sports to relay them.

The invention discloses a deoxymononucleotide natrium-containing drug composition and applications thereof, and belongs to the technical field of medicine. The deoxymononucleotide natrium-containing drug composition contains deoxyribose adenine nucleotide natrium, deoxyribose thymine nucleotide natrium, deoxyribose guanine nucleotide natrium, and deoxyribose cytosine nucleotide natrium, wherein a weight ratio of the deoxyribose adenine nucleotide natrium to the deoxyribose thymine nucleotide natrium to the deoxyribose guanine nucleotide natrium to the deoxyribose cytosine nucleotide natrium is (3-10):(2-13):(2-11):(1-10). The deoxymononucleotide natrium-containing drug composition has excellent effects in clinic, particularly in adjunctive treatments of acute hepatitis and chronic hepatitis.

The invention relates to the technical field of preparation of polypropylene anti-corrosion materials, and discloses a polypropylene anti-corrosion material based on a biomass cytosine flame retardant, the polypropylene anti-corrosion material comprises the following raw materials in parts by weight: a cytosine flame retardant, polypropylene, an antioxidant and a toughening agent, wherein the toughening agent is a mixture of an ethylene-vinyl acetate copolymer, a thermoplastic elastomer and powdered rubber. According to the polypropylene anti-corrosion material based on the biomass cytosine flame retardant, tris (epoxypropyl) isocyano cytosine nucleotide is prepared from cytosine derivatives by condensation reaction between cytosine nucleotides and tris (epoxypropyl) isocyanurate, aluminumhydroxide is added to react with phosphoric acid groups to generate a salt, and a biomass cytosine aluminum salt with flame retardant effect is obtained; and the flame retardant improves the integrity of the polypropylene material in forming expanded carbon morphology, makes surface layer carbon of a carbon layer compact and the inner layer porous, thereby effectively improving the flame retardant efficiency of the polypropylene material, and has small addition amount and good flame retardant effect.

The present disclosure provides modified microRNA nucleic acid compositions that have one or more cytosine and / or uracil bases replaced with gemcitabine or a 5-halouracil, respectively. More specifically, the present disclosure reveals that the replacement of cytosine nucleotides within a microRNA nucleotide sequence with a gemcitabine molecule increases the ability of the microRNA to inhibit cancer progression and tumorigenesis. In addition, the present disclosure reveals that the replacement of cytosine nucleotides within a microRNA nucleotide sequence with a gemcitabine molecule and replacement of uracil bases with 5-halouracil increases the ability of the microRNA to inhibit cancer development. As such, the present disclosure provides various modified nucleic acid (e.g., microRNA) compositions having gemcitabine molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions comprising the modified nucleic acid compositions, and methods for treating cancers using the same.

The invention discloses a preparation method of an electrochemical biosensor for simultaneously detecting Exo I and TdT. Sulfhydryl DNA and a gold electrode surface form an Au-S covalent bond spontaneously by a mercapto part and the sulfhydryl DNA is fixed on the gold electrode surface. Polymerization of the 3'-OH tail of the TdT catalytic sulfydryl DNA and dCTP is carried out and a generated rich-C DNA long chain can used for forming AgNCs; and the TdT activity is detected by a dissolved voltammetric signal of Ag. Before TdT polymerization, Exo I is introduced and the sulfhydryl DNA can be hydrolyzed, so that the formation of AgNCs is affected finally; and thus the ExoI activity is detected. The electrochemical signal intensity can be affected by changing the ExoI or TdT concentration; and on the basis of the principle, a high-efficiency electrochemical biosensor for simultaneously detecting Exo I and TdT is prepared.

The invention belongs to the technical field of biology, and particularly relates to an engineering bacterium containing nCas3 single-stranded endonuclease as well as a preparation method and application of the engineering bacterium. The functional structure division of the Cas3 protein of the ZM4 strain is found by comparing the difference of the coding gene sequences of the ZM4 strain, other strains which also carry an endogenous I-type CRISPR-Cas system and endogenous CRISPR-related proteins. An amino acid in a Cas3 protein helicase structural domain in the ZM4 strain is designed and replaced by exploring the working principle of the I-F type CRISPR-Cas system. According to the method, adenine nucleotides 676 and 661 in ZMO0681 genes for coding Cas3 protein on an original ZM4 strain are replaced with cytosine nucleotides in situ, so that the Cas3 protein loses helicase activity and is converted into nCas3 protein only carrying single-stranded DNA endonuclease activity, and therefore, a modified strain DRM2 is obtained.

Provided are methods for characterizing nucleotide accessibility and nucleic acid structure at single nucleotide resolution, using a combination of low-yield bisulfite conversion and next-generation sequencing (NGS). Cytosine (C) nucleotides that are in base-paired states or bound to proteins, etc. are less accessible to chemical reactions and thus exhibit lower bisulfite conversion yields. Analysis of NGS results of a low-yield bisulfite conversion product can thus inform nucleotide accessibility and nucleic acid structure. Compared to other methods for chemical probing of nucleic acid structure, the present methods provide higher information throughput, because each NGS read simultaneously reports on the base pair status of multiple nucleotides.

The invention discloses a quality control method for ribonucleic acid II for injection. The method comprises the following steps that the nucleic acid enzyme hydrolysis solution of a substance to be measured is subjected to high-performance liquid chromatogram analysis, an adopted chromatographic column is an Agilent ZORBAX SB-AQC18 chromatographic column, and a flowing phase is a mixture of a formic acid solution and an acetonitrile solution; after the analysis, if the substance to be measured is determined to contain five substances as follows: cytidylate, uridine monophosphate, guanine nucleotide, guanosine and adenosine, the substance to be measured is the ribonucleic acid II for injection or is the ribonucleic acid II for injection as a candidate; and if not, the substance to be measured is not the ribonucleic acid II for injection or is not the ribonucleic acid II for injection as the candidate. A high-performance liquid chromatographic technique is utilized, and the strong-specificity quality control method for the ribonucleic acid II for injection is established. The method has important meanings on increasing the technological content of the medicine, increasing the safety and effectiveness, reducing the cost, enlarging the production scale, increasing the market occupancy, and going forward to the international market.

The present invention relates to an isolated polynucleotide encoding a Na+ / K+ ATPase polypeptide useful in methods to identify therapeutic agents useful for treating cardiovascular diseases, the polynucleotide is selected from the group consisting of:SEQ ID 4 and SEQ ID 5 (baySNP-1765) with allelic variation G in position 240 contained in a functional surrounding like full length cDNA for Na+ / K+ ATPase and with or without the Na+ / K+ ATPase promotor sequence; and SEQ ID 4 and SEQ ID 5 (baySNP-1765) with allelic variation A in position 240 contained in a functional surrounding like full length cDNA for Na+ / K+ ATPase and with or without the Na+ / K+ ATPase promotor sequence.The invention also provides diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. The invention provides further polymorphic sequences and other genes.